YWYadong Wang

Yadong Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yadong Wang has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development and validation of an immune-related gene prognostic model for stomach adenocarcinoma

    by Ming Wu, Yu Xia, Yadong Wang, Fei Fan, Xian Li, Jukun Song, Jie Ding

    Purpose: Stomach adenocarcinoma (STAD) is one of the most common malignant tumors, and its occurrence and prognosis are closely related to inflammation. The aim of the present study was to identify gene signatures and construct an immune-related gene (IRG) prognostic model in STAD using bioinformatics analysis. Methods: RNA sequencing data from healthy samples and samples with STAD, IRGs, and transcription factors were analyzed. The hub IRGs were identified using univariate and multivariate Cox regression analyses. Using the hub IRGs, we constructed an IRG prognostic model. The relationships between IRG prognostic models and clinical data were tested. Results: A total of 289 differentially expressed IRGs and 20 prognostic IRGs were screened with a threshold of P<0.05. Through multivariate stepwise Cox regression analysis, we developed a prognostic model based on seven IRGs. The prognostic model was validated using a GEO dataset (GSE 84437). The IRGs were significantly correlated with the clinical outcomes (age, histological grade, N, and M stage) of STAD patients. The infiltration abundances of dendritic cells and macrophages were higher in the high-risk group than in the low-risk group. Conclusions: Our results provide novel insights into the pathogenesis of STAD. An IRG prognostic model based on seven IRGs exhibited the predictive value, and have potential application value in clinical decision-making and individualized treatment.


  • Clinical management of lung adenocarcinoma patients with HER2 V659E mutation.

    by Ziqi Jia, Naixin Liang, Yadong Wang, Yanyu Wang, Junyi Ye, Weiwei Wang, Bing Li, Han Han-Zhang, Jiaxing Zhao, Xiaochun Zhang, et al.

    E21521 Background: ERBB2 mutations, mostly affecting the kinase domain (KD), were later found in the transmembrane domain (TMD), most frequently seen in residues V659, G660, but with a much lower prevalence. Comparing to other solid tumors, ERBB2-mutant NSCLC shows a lower response rate to HER2 inhibitors (HER2i). ERBB2 V659E has been reported to respond to lapatinib in combination with carpecitabine, afatinib, or ado-trastuzumab emtansine (TDM-1). However, since the prevalence of ERBB2 V659E is low, no study has reported the subsequent clinical management after developing resistance to HER2i. Methods: We retrospectively screened genomic profiles of 7,812 lung adenocarcinoma (LADC) patients. Molecular docking of lapatinib, afatinib and pyrotinib with the HER2 KD was simulated with AutoDock 4.2 and the binding affinity was predicted by MMPBSA.py program in AmberTools18. Results: We analyzed NGS data of 7812 LADC patients and identified 14 patients (0.18%) with HER2 TMD mutation, mostly V659E mutation (11/7812, 0.14%); other mutations included V664F, T652M, V664F; each occurred in 1 patient. In this cohort, all adenocarcinomas harbor a dinucleotide missense mutation, including 10 TT→AA and 6 TT→AG (c.1976_1977). TP53 was the most frequently co-mutated gene (n = 4) followed by HER2 (n = 2), NSD1 (n = 2) and RARA (n = 2). Treatment history of 9 advanced LADC patients were collected and analyzed. 3 of them had chemotherapy as first-line therapy. 5 patients were treated with HERi as first-line therapy, achieving a median PFS of 192 days (ranged from 60-515days), comparing to patients treated with chemotherapy (71.7±53.3days). 1 patient who was treated with different HERi sequentially in the order of lapatinib, afatinib, TDM-1, achieving an overall PFS of 515 days. Subsequently, she was treated with pyrotinib and had a PFS of 92 days. Molecular docking simulation showed the covalent inhibitors Afatinib and Pyrotinib are more favorable for blocking HER2 KD than non-covalent inhibitor Lapatinib. Between the two covalent inhibitors, Pyrotinib (∆GPyrotinib = -65.92kcal/mol) shows stronger non-covalent binding ability than Afatinib (∆GAfatinib = -59.71 kcal/mol) (p < 0.001). Conclusions: To the best of our knowledge, this is the largest-reported HER2 V659E mutation cohort. We revealed the prevalence of ERBB2 V659E in Chinese LUAD patients and elucidated the genomic profile of ERBB2 V659E mutant. This study paves avenue for the utilization of the novel HER2 inhibitors pyrotinib in ERBB2 V659E mutant LUAD patients.